Finasteride, bicalutamide and nilutamide discontinued at least  weeks prior to registration
Patients must have discontinued all biologic therapy at least  days before participation
Patients who are receiving any other investigational agents; all investigational agents other than ibrutinib must have been discontinued at least  weeks prior to beginning treatment; prior ibrutinib therapy must have been discontinued at least  weeks prior to beginning therapy
Prior chemotherapy, other investigational agents, or radiation must be discontinued for at least  days prior to the first administration of COTI-. Hormone treatments must be discontinued for at least  days prior to the first administration of COTI-.
All previous cancer therapy (with the exception of hydroxyurea) including donor lymphocyte infusions must have been discontinued at least  weeks prior to treatment in this study
Previous systemic anti-cancer therapy must have been discontinued at least  weeks prior to treatment in this study; if there is progression of disease on that therapy and all adverse effects have resolved to grade  or baseline, in which case  weeks is acceptable
Previous radiation, hormonal therapy, and surgery must have been discontinued at least  weeks prior to treatment in this study and adverse effects must have resolved; lymph node or other diagnostic biopsy within  weeks is not considered exclusionary
All previous cancer therapy including radiation, chemotherapy, and surgery, must have been discontinued at least  weeks prior to treatment in this study
Subjects with concurrent cytotoxic chemotherapy or radiation therapy; there must be at least  days between any other prior chemotherapy (or radiotherapy) and study treatment; prior antibody therapy must be discontinued  weeks prior to start of study treatment
Have discontinued previous treatments for cancer.
Patients must have discontinued all biologic therapy at least  days prior to registration
Previous anticancer treatment must be discontinued at least  weeks prior to the initiation of study treatment ( weeks for mitomycin C;  weeks for anti-androgen therapy if discontinued prior to treatment initiation, except  weeks for bicalutamide);
Discontinued all previous treatments for cancer ? weeks prior.
Discontinued use of chemotherapy, radiation therapy, or growth factors for at least  weeks prior to first study treatment, with the exception of hydroxyurea.
PHASE I: Any prior radiation therapy must be discontinued at least four weeks prior to enrollment
PHASE II: Any prior radiation therapy must be discontinued at least four weeks prior to enrollment
Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, biologic therapy) other than the ones specified in the protocol; patients must have discontinued the above cancer therapies for  week prior to the first dose of study medication; any investigational drugs should be discontinued  weeks prior to the first dose of study medication and radiotherapy must have been completed >=  weeks prior to initiation of study drug (cycle , day )
Systemic chemotherapy/radiotherapy/investigational therapy within  days (with the exception of hydroxyurea and steroids) prior to starting therapy; for patients receiving ALL maintenance with -mercaptopurine, methotrexate, vincristine, and steroids - these agents should be discontinued at least  hours prior to start of study drugs; for patients on oral targeted therapies (such as imatinib, dasatinib, ponatinib), - these agents should be discontinued at least  hours prior to start of study drugs
Prior systemic treatment was discontinued for at least  weeks prior to the Baseline Visit.
Patients must have discontinued all previous biologic therapies and recovered from side effects due to biologic treatment for more than  days prior to starting on treatment
Previous radiation and/or surgery must have been discontinued or completed at least  weeks prior to treatment in this study and adverse effects must have resolved to grade  or baseline; lymph node or other diagnostic biopsies within  weeks are not considered exclusionary\r\n* CTCL patients who have received localized radiation therapy (RT) as part of their immediate prior therapy may be allowed to enroll with shorter washout period after discussion with the MSK principal investigator
Prior use of duvelisib if discontinued due to toxicity
Any prior therapy for B-CLL must have been discontinued >= -days prior to registration
Prior Therapies: Systemic treatments: must have discontinued previous systemic treatments for cancer and recovered from the acute effects of therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy at least  days and have discontinued any cytotoxic therapies at least  days prior to study enrollment. Radiation therapy and surgery: must be completed at least  weeks before study enrollment
Patients may have received prior therapy (including chemotherapy, biologic/targeted therapy and immunotherapy) for treatment of endometrial cancer; all therapy must be discontinued at least  weeks prior to registration; any investigational agent must be discontinued at least  days prior to registration
The subject must have discontinued any endocrine therapy for at least  weeks before the first dose of study treatment; in the cases of fulvestrant and leuprolide, these must be discontinued for at least  weeks before the first dose of study treatment
Any prior radiation therapy must be discontinued at least four weeks prior to registration
Prior taxane therapy for metastatic breast cancer is allowed if the patient received ?  full cycle (i.e., therapy discontinued within  weeks for subjects receiving weekly paclitaxel or Abraxane; therapy discontinued within  weeks for subjects receiving paclitaxel or docetaxel every  weeks) in the absence of progression or if taxane therapy for metastatic disease was >  months prior to CD-.
Have discontinued previous treatments for cancer;
Any prior radiation therapy must be discontinued at least four weeks prior to registration.
Previous chemotherapy for local recurrence is allowed but must have been discontinued at least  weeks before receiving the study drug and the patient must have recovered from acute adverse effects
Bicalutamide (Casodex) and nilutamide discontinued <  weeks prior to registration
Previous radiation, hormonal therapy, and/or surgery must have been discontinued or completed at least  weeks prior to treatment in this study and adverse effects must have resolved; lymph node or other diagnostic biopsies within  weeks are not considered exclusionary
Prior therapy with romidepsin if discontinued due to toxicity
Other investigational drugs within  weeks prior to enrollment, unless cleared by the principal investigator; previous fixed-dose IL- therapy that was discontinued prior to  weeks is permitted
Any prior radiation therapy must be discontinued at least  weeks prior to study treatment initiation
Participants may have had any number of previous hormonal therapies (antiandrogens including enzalutamide, estrogens, finasteride, dutasteride, ketoconazole) provided these were discontinued >=  weeks before starting the trial; prior therapy with steroids is allowed though these must be discontinued >=  weeks before starting the trial; inhaled, topical, and intra-articular steroids are allowed
Participants may have had up to two previous cytotoxic therapeutic regimens provided these were discontinued >=  weeks before starting the trial
Previous systemic anti-cancer therapy must have been discontinued at least  weeks prior to treatment in this study; if there is progression of disease on that therapy and all adverse effects have resolved to grade  or baseline, in which case  weeks is acceptable
Prior everolimus and/or sunitinib therapy is allowed, so long as it was discontinued >=  weeks prior to randomization
Patients who have received systemic anti-cancer therapy such as chemotherapy, immunotherapy and/or biologic therapy =<  weeks prior to study entry; concurrent anti-cancer therapy (chemotherapy, immunotherapy, biologic therapy) other than the ones specified in the protocol is not permitted during study participation; patients must have discontinued the above cancer therapies for  weeks prior to the first dose of study medication, as well as recovered from toxicity (to =< than grade , except for alopecia) induced by previous treatments; any investigational drugs should be discontinued  weeks prior to the first dose of study medication
Previous systemic anti-cancer therapy must have been discontinued at least  weeks prior to treatment in this study; if there is progression of disease on that therapy and all adverse effects have resolved to grade  or baseline, in which case  weeks is acceptable
Previous radiation, hormonal therapy, and surgery must have been discontinued or completed at least  weeks prior to treatment in this study and adverse effects must have resolved; lymph node or other diagnostic biopsy within  weeks is not considered exclusionary
Prior therapy with romidepsin if discontinued due to toxicity
Chemotherapy within  weeks prior to screening are excluded (other than hydroxyurea at stable doses and will be discontinued  hours prior to starting study drug)
All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least  weeks prior to treatment in this study
No prior systemic therapy for lymphoma including chemotherapy or immunotherapy. Patients may have received involved-field radiation therapy which has been discontinued at least  weeks prior to treatment in this study.
All previous therapy not associated with peripheral blood stem cell transplant, including radiation, hormonal therapy, and surgery, must have been discontinued  weeks prior to treatment in this study
Any prior radiation therapy must be discontinued at least four weeks prior to registration
All previous cancer therapy including chemotherapy, radiation, hormonal therapy and surgery, must be discontinued ? weeks prior to registration.
Systemic treatments: Must have discontinued previous systemic treatments for cancer and recovered from the acute effects of therapy. Participants must have discontinued:
Discontinued prior systemic treatment or any investigational drug for at least  weeks ( days) or for at least  weeks for IV anti-cancer drugs, prior to the study randomization
All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least  weeks prior to treatment in this study
Discontinued all previous cancer therapies, and any agents that have not received regulatory approval, for at least  days and recovered from the acute effects of therapy. Must have discontinued mitomycin-C or nitrosourea therapy for at least  days.
All previous therapies must have been discontinued at least  weeks prior to initiation of the administration of this studys drugs
Patients who have received previous cytotoxic chemotherapy including an AC-T regimen or previous therapeutic radiation therapy for any reason in the last  years; because of possible limitations in bone marrow reserve, patients with such prior treatments are not appropriate candidates for this trial; patients who have had prior hormonal therapy (for instance, tamoxifen for prevention of breast cancer) are eligible; patients who have participated in a window study (treatment with an investigational agent prior to surgery for =<  weeks) are eligible but must have discontinued the investigational agent at least  days before enrollment
Targeted therapy must have been discontinued =<  days prior to initiation of study therapy
Use of plaquenil must be discontinued two weeks prior to first study treatment
Treatment with chemotherapy or biologic therapy within  weeks, except for hydroxyurea, which must be discontinued prior to treatment on study
Receiving hormone replacement therapy that cannot be discontinued
